Ovarian cancer (OC) remains a fatal malignancy because most patients experience
recurrent disease, which is resistant to chemotherapy. The outcomes for patients with …

Epithelial ovarian cancer is a highly heterogeneous disease characterized by multiple
histological subtypes. Molecular diversity has been shown to occur within specific …

Advanced and recurrent gynecological cancers are associated with poor prognosis and lack
of effective treatment. The developments of the molecular mechanisms on cancer …

Purpose The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines the biologic
activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to …

There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein
kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since …

Sustained and complete inhibition of HER3 and its output to PI3K/Akt are required for the
optimal antitumor effect of therapeutic inhibitors of the HER2 oncogene. Here, we show that …

Ovarian cancer is the most deadly gynecologic malignancy, with more than 15,000 deaths
anticipated in 2012.1 While approximately 80% of patients will respond to frontline …

Purpose To determine whether the antibody-drug conjugate trastuzumab emtansine (T-
DM1), which combines human epidermal growth factor receptor 2 (HER2)–targeted delivery …

We examined the effects of an inhibitor of PI3K, XL147, against human breast cancer cell
lines with constitutive PI3K activation. Treatment with XL147 resulted in dose-dependent …

Although anti-HER2 (human epidermal growth factor receptor 2) therapy is currently
approved for breast, gastric, and gastroesophageal cancers overexpressing the HER2 …